Skip to main content

stock

VICP · Vicapsys Life Sciences, Inc.

What Vicapsys Life Sciences, Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live VICP price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on VICP.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
Not reported.

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
—
Net
—

Returns

ROE
—
ROA
-1504.4%

Health

Current ratio
0.0x
Debt/equity
—

Deep value

NCAV
—
NCAV per share
—
Price/NCAV
Locked
NNWC
—
NNWC per share
—
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2024-09-30; balance sheet at 2024-09-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenue (not reported by this company)Gross profit (not reported by this company)Operating incomeNet incomeFiling
2024-09-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$198,862-$235,507
10-Q filed 2025-01-10
2024-06-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$181,841-$190,091
10-Q filed 2025-01-10
Assembled from more than one filing; the filing above is only the newest of them.
2024-03-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$204,255-$327,072
10-Q filed 2025-01-10
Assembled from more than one filing; the filing above is only the newest of them.
2023-12-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$524,585-$594,802
10-K filed 2024-10-21
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2023-09-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$175,423-$240,340
10-Q filed 2025-01-10
2023-06-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$135,693-$135,693
10-Q filed 2025-01-10
Assembled from more than one filing; the filing above is only the newest of them.
2023-03-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$211,277-$211,277
10-Q filed 2025-01-10
Assembled from more than one filing; the filing above is only the newest of them.
2022-12-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$492,606-$492,606
10-K filed 2024-10-21
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assets
$89,569
Equity
-$2.65M

Balance as of 2024-09-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2023-12-31—-$1.05M-$1.18M—
2022-12-31—-$984,790-$984,790—
2021-12-31—-$336,871-$236,871—
2020-12-31—-$765,844-$765,844—
2019-12-31——-$1.41M—

Company filings

Insiders, politicians and funds

Insider trades, last 90 days

No insider buys or sales filed in the last 90 days.

Politician trades, last 90 days

Funds

News

Stories that named VICP, and the market events around them.

Sign in to see this

Board

The VICP board could not be loaded.

Retry the VICP board

nakagai

Signals on VICP come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the VICP board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

Vicapsys Life Sciences, Inc. (VICP): SEC filings, financials and insider trades · Nakagai